07 November 2017 | News
Azacitidine is a bioequivalent generic version of VIDAZA® approved by Health Canada
Dr. Reddy’s Laboratories Ltd. has announced the launch of generic Azacitidine for injection 100 mg/vial in the Canadian Market.
Azacitidine is a bioequivalent generic version of VIDAZA® approved by Health Canada.
Alok Sonig, Executive Vice President and Head of the North America Generics business, Dr. Reddy’s Laboratories said, “Bringing Azacitidine for Injection to the Canadian market at this time is very important for us, as well as for our customers and their patients. This launch represents Dr. Reddy’s commitment to make affordable injectable drugs available in Canada.”
Dr. Reddy’s is first to market with this Azacitidine for injection in Canada.
Vinod Ramachandran, Ph.D., Country Manager, Dr. Reddy’s Canada said, “The approval and launch of Azacitidine for injection is an important milestone for Dr. Reddy's in Canada. The launch of first generic Azacitidine for injection is another step in our long-term commitment to bring more cost-effective options to Canadian patients.”